Please assess the completion status of the following clinical trial:

Trial Title: CKD-11101 Phase 3 SC Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria~  1. Patients with 19 years of age or older~ 2. Patients with chronic renal failure of stage 3 or above who are not on dialysis~ 3. Patients with the Hb levels of 8 to 10g/dl measured at screening~ 4. Patients with enough body iron stores who meet the following item:~     -Serum ferritin ≥ 100ng/ml or Transferrin saturation ≥ 20%~ 5. Patients who have provided written consent to participate in the clinical trial voluntarily~* Exclusion Criteria~  1. Patients who are expected to need dialysis within a year or patients with rapidly progressive chronic renal failure~ 2. Patients who have received drug treatment such as erythropoiesis stimulating agent for the purpose of correcting anemia within 12 weeks prior to screening~ 3. Patients who have received red blood cell transfusion within 12 weeks prior to screening~ 4. Patients with uncontrolled hypertension~ 5. Patients who had hypersensitivity to erythropoietin agents~ 6. Patients who had known hypersensitivity to mammalian cell-derived products or additives~ 7. Patients with history of severe cardiovascular diseases~ 8. Patients whose anemia is not caused by chronic renal failure or may affect anemia correction including the following conditions:~ 9. Patients whose AST/ALT test results performed at screening exceeds twice of normal upper limit~ 10. Patients who have experience of positive result in anti-erythropoietin antibody in previous treatment with erythropoiesis stimulating agent

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CKD-11101(Darbepoetin alfa) (Type: EXPERIMENTAL): The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
- NESP(Darbepoetin alfa) (Type: ACTIVE_COMPARATOR): The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.

Based on this trial design, predict the completion outcome and termination type (if applicable).